Fortress Biotech (FBIO) Net Cash Flow Growth (1y) (2011 - 2025)
Powered by 
Analysis
Fortress Biotech (FBIO) Net Cash Flow Growth (1y) (2011 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 149.49% |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -104.22% |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -225.42% |
| Sep 30, 2025 | 168.20% |
| Jun 30, 2025 | -123.86% |
| Mar 31, 2025 | 1,265.05% |
| Dec 31, 2024 | -124.37% |
| Sep 30, 2024 | -19.93% |
| Jun 30, 2024 | 88.48% |
| Mar 31, 2024 | 109.50% |
| Dec 31, 2023 | 129.10% |
| Sep 30, 2023 | 64.21% |
| Jun 30, 2023 | -69.62% |
| Mar 31, 2023 | -42.78% |
| Dec 31, 2022 | -155.26% |
| Sep 30, 2022 | -81.49% |
| Jun 30, 2022 | -159.91% |
| Mar 31, 2022 | -132.24% |
| Dec 31, 2021 | 258.23% |
| Sep 30, 2021 | -210.35% |
| Jun 30, 2021 | -131.49% |
| Mar 31, 2021 | 6,279.89% |